



Guest Editor



Cristina P. R. Xavier, PhD

i3S - Institute of Health Research and Innovation, University of Porto, Porto, Portugal

cristinax@ipatimup.pt

Targeting the tumor microenvironment for cancer treatment

Deadline: 31 December 2022

Dear Colleagues,

Several evidences have shown that the tumor microenvironment (TME) can reprogram tumor initiation, growth, invasion, metastasis, and response to therapies. Indeed, the TME has been recognized as a major contributor to cancer malignancy and therapeutic resistance. The TME comprises the surrounding blood vessels, signaling molecules, the extracellular matrix (ECM) and multiple stromal cells, including cancer-associated fibroblast (CAFs), tumor-associated macrophages (TAMs), among others. The presence of these cellular components has been associated with poor prognosis and unfavorable outcomes in different types of cancers. Therefore, therapies that simultaneously target tumor cells and TME components may represent a key strategy to overcome drug resistance and improve patient outcomes. This Special Issue includes original research articles focusing on novel bioactive compounds or small molecules (chemically synthesized or of natural origin), or repurposed drugs, that target TME elements to improve cancer therapy. Review articles will also be considered.

Dr. Cristina P. R. Xavier

Guest Editor